Zoetis Inc.

NYSE:ZTS

Drug Manufacturers - General

Healthcare
$85.55 +1.51%

+$1.17 today

Market cap
$34.76B
Beta
0.74
P/E (TTM)
12.5
EPS (TTM)
$6.26
Dividend yield
2.63%
52W Low $72.38High $161.77

Volume 4.66M

Average 6.20M

ZTS Interest Expense

Cost of servicing the company's debt during the period.

Zoetis Inc.NYSE: ZTS

Interest Expense · Q2 FY2026 · quarter ended Jun 2026

Interest expense grows in line with its trailing trend

Q2 FY2026 interest expense of $61M rose 5.2% year over year, ahead of the +4.3% change in trailing-twelve-month interest expense. Sequentially, it fell 1.6% from the prior quarter. Over 3 fiscal years it compounded at +0.8% a year.

Context

  • Interest expense amounted to 2.6% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +5.2% holds above the trailing-twelve-month pace of +4.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$61M-1.6% QoQ
Last fiscal yearDec 2025
$243M+0.4% YoY
LTMJun 2026
$244M+4.3% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.2%——
1 year+0.4%——
3-year CAGR+0.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
243M USD
Year-over-year change
+0.4%
4-year CAGR
+0.7%

Interest Expense vs competitors

How ZTS compares with its peers on the latest reported figures

  • ZTS's LTM Jun 2026 interest expense of $244M is the 3rd highest of the 6 companies compared; the peer median is $56.45M.
  • Its year-over-year change of +4.3% is the 3rd highest of 6, against a peer median of -1.0%.
  • Interest expense amounts to 2.6% of revenue for ZTS, versus a peer median of 3.1%.
ZTS Competitors Peer median
Interest Expense for ZTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MRKMerck & Co., Inc.LTM Jun 2026$1.26B -1.0%+12.2%1.9%
ELANElanco Animal Health IncorporatedLTM Sep 2026$266M +12.2%-4.9%5.2%
ZTSZoetis Inc.LTM Jun 2026$244M +4.3%+0.8%2.6%
NEOGNeogen CorporationLTM Aug 2026$56.45M -18.7%+1.0%6.4%
PAHCPhibro Animal Health CorporationLTM Mar 2026$45.88M +26.8%+40.1%3.1%
IDXXIDEXX Laboratories, Inc.LTM Sep 2026$28.44M -23.4%-1.4%0.6%
Peer median (excluding ZTS) $56.45M-1.0%+1.0%3.1%

Competitors are the stored peer set for ZTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.78B8.08B8.54B9.26B9.47B
Cost of Revenue2.46B2.6B2.71B2.86B2.79B
Gross Profit5.31B5.48B5.83B6.4B6.67B
Gross Margin68.3%67.8%68.3%69.1%70.5%
Research & Development508M539M614M686M698M
Selling, General & Admin2B2.01B2.15B2.32B2.38B
Operating Expenses2.51B2.55B2.77B3B3.08B
Depreciation & Amortization448M465M491M497M487M
EBITDA3.17B3.36B3.69B3.87B4.07B
EBITDA Margin40.8%41.6%43.1%41.8%43.0%
Operating Income2.8B2.93B3.07B3.39B3.6B
Operating Margin36.0%36.2%35.9%36.6%38.0%
Interest Income6M50M105M106M93M
Interest Expense236M237M258M242M243M
Other Income / Expenses(315M)(272M)(133M)(259M)(237M)
Income Before Tax2.49B2.66B2.94B3.13B3.36B
Pre-Tax Margin32.0%32.9%34.4%33.8%35.5%
Income Tax Expense454M545M596M637M687M
Net Income2.04B2.11B2.34B2.49B2.67B
Net Margin26.2%26.2%27.4%26.9%28.2%
EPS (Basic)4.294.515.085.476.03
EPS (Diluted)4.274.495.075.476.02
Weighted Avg Shares474.35M468.89M461.17M454.2M443.44M
Weighted Avg Shares (Diluted)476.72M470.39M462.27M454.85M443.84M

Zoetis Inc.

NYSE:ZTS

Intrinsic Alpha fair value

Locked

Current Price

$85.55

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.